Dupilumab treatment in adult patients is efficacious regardless of age at atopic dermatitis onset

湿疹面积及严重程度指数 杜皮鲁玛 医学 特应性皮炎 安慰剂 发病年龄 内科学 年轻人 胃肠病学 儿科 皮肤病科 疾病 病理 替代医学
作者
Jonathan I. Silverberg,Kim Alexander Papp,P. de la Cueva,H. Zhang,Ainara Rodríguez Marco,Noah A. Levit
出处
期刊:Revue Francaise D Allergologie [Elsevier BV]
卷期号:62 (3): 324-325
标识
DOI:10.1016/j.reval.2022.02.086
摘要

Adult-onset AD accounts for ∼25% of adult patients (pts) and is described to have clinical characteristics distinct from childhood-onset AD. To report dupilumab efficacy in adults with moderate-to-severe AD, stratified by age of AD onset. In LIBERTY AD SOLO 1 and 2 (NCT02277743, NCT02277769), 2 identically designed phase 3 trials, 1379 pts aged ≥ 18 years with moderate-to-severe AD received subcutaneous dupilumab 300 mg every 2 weeks (q2w) or weekly (qw), or placebo (PBO) qw, for 16 weeks. Least squares (LS) mean percent change (standard deviation [SD]) from baseline (BL) in Eczema Area and Severity Index (EASI) and weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) scores in pts who received dupilumab q2w (n = 457) vs. PBO (n = 460) by age of AD onset are reported. Age of AD onset was self-reported; P values compared to the corresponding PBO are nominal: **P < 0.01, ***P < 0.001, ****P < 0.0001. In the dupilumab/PBO groups, mean age and duration of AD were 38.3/38.4 years and 27.9/28.8 years, respectively. BL distribution of age of AD onset (n [%]) in the < 5 years, 5–9 years, 10–19 years and ≥ 20 years age groups was 239 (52.3)/249 (54.1), 61 (13.3)/67 (14.6), 63 (13.8)/60 (13.0) and 91 (19.9)/79 (17.2), respectively, for the dupilumab/PBO arms. Disease severity measured by mean EASI and mean weekly PP-NRS showed high consistency at baseline across age of onset groups. At week 16, statistically significant improvements in EASI and PP-NRS scores were observed in the dupilumab vs. PBO groups in all age of onset groups: EASI, −69.7**** vs. −32.0, −65.8*** vs. −37.5, −70.0**** vs. −35.0, −70.4**** vs. −38.7; PP-NRS, −48.3**** vs. −18.6, −46.0** vs. −25.3, −39.3** vs. −18.3, −46.0**** vs. −19.1. Dupilumab was generally well tolerated, with an acceptable safety profile. Dupilumab is efficacious in adults regardless of age at AD onset. Approximately 1 in 5 adults reported onset of AD in adulthood. Total EASI scores were comparable by age of onset, and dupilumab had similar efficacy on EASI and PP-NRS scores during 16 weeks of treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
这波你的吗完成签到 ,获得积分10
1秒前
刘晨发布了新的文献求助10
1秒前
xucc发布了新的文献求助10
1秒前
在水一方的应助被syh采纳,获得10
1秒前
2秒前
王博龙完成签到,获得积分10
2秒前
3秒前
腼腆的眼睛完成签到 ,获得积分10
3秒前
hana发布了新的文献求助10
3秒前
3秒前
东方完成签到,获得积分10
3秒前
丘比特的应助被苦瓜大王采纳,获得10
3秒前
3秒前
liuis完成签到,获得积分10
4秒前
4秒前
Jasper的应助被一滩烂泥采纳,获得10
4秒前
Lotus完成签到,获得积分10
4秒前
洞洞幺发布了新的文献求助10
4秒前
大绿豆cc发布了新的文献求助10
4秒前
5秒前
忱麓裔发布了新的文献求助10
5秒前
7秒前
ke完成签到,获得积分10
7秒前
Jupiter发布了新的文献求助10
7秒前
7秒前
ypz发布了新的文献求助10
7秒前
雨天完成签到,获得积分10
7秒前
Overlap完成签到 ,获得积分10
7秒前
靓丽芙蓉完成签到,获得积分10
7秒前
islazheng发布了新的文献求助10
8秒前
8秒前
丁丁当当发布了新的文献求助10
8秒前
9秒前
李健的应助被小羊采纳,获得10
9秒前
科研通AI2S的应助被mike采纳,获得10
10秒前
YUYUYU发布了新的文献求助10
10秒前
空瓶氧气发布了新的文献求助10
11秒前
heoouijee发布了新的文献求助10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417